INCYTE REACHES AGREEMENT WITH FDA ON MF DRUG
MPNRF | May 3, 2020
July 22, 2009
The COMFORT-1 (COntrolled MyeloFibrosis Study with ORal Jak Treatment) trial will test the drug INCB18424 in patients with Primary Myelofibrosis, post-Polycythemia Vera Myelofibrosis or post-Essential Thrombocythemia Myelofibrosis. The Special Protocol Assessment (SPA) for the design of the trial is related to reduction in spleen size, a goal Incyte is confident they will meet.
The trial, which will begin in August, has recruited 240 patients.